One observed. TH h Hematological toxicity t All patients were MDV3100 evaluable for toxicity T and patients had side effects of degree. A summary of the toxicity Dermatological treatment resulting t h Nonhaematological th order with the packing in the table and presents DLT was observed, are shown in Table b. The most important hint or th h Hematological toxicity t was neutropenia, febrile neutropenia and one patient had thrombocytopenia. A patient treated with a dose of neutropenia. Tthe dose were h Hematological toxicity t th e F Observed quality t, but only in the cycle were thrombocytopenia and was considered a DLT. MTD dose in patients h Hematological toxicity t h t degrees. One patient developed thrombocytopenia degree doselimiting w W During the cycle. Tin were more severe h Observed hematological side effects pm.
Two patients developed a DLT, which consisted of neutropenia in patients with febrile neutropenia CHIR-258 and Grade Grade Grade thrombocytopenia and electrolyte imbalance in the other patients. Dose, the patient developed h Hematological toxicity Th Nth degree, but not w W During the cycle. Therefore, these events were not considered DLT. Since Th h h Hematological toxicity t. Three patients, a dose reduction of tipifarnib and gemcitabine five patients t The major signs of toxicity T or Nonhaematological Nonhaematological Th toxicity t were nausea, vomiting and fatigue. nausea and vomiting often occurred in the first week of each cycle, when administered tipifarnib.
In many Cases the addition of tipifarnib was so difficult to report because of the nausea, the seen worse than in the monotherapy trials seemed Zujewski Karp et al et al et al Crul dose of pulmonary embolism in a patient ww During the cycle t quality t. Cans and several degrees of toxicity Nonhaematological E t observed, though. These events as dose-limiting side effects w Developed in subsequent cycles A patient treated with a dose increased FITTINGS ALT levels Ht, but it was paid for train Accessible. This T toxicity T was clearly not associated with the study medication, and it was decided to treat the patient at the same doses of three drugs on. This new procedure without incident provocation. Box, the patient also nonhaematological toxicity Tsgrad How is a patient at this dose level had a DLT, which consisted of neutropenia, thrombocytopenia, and electrolyte imbalance.
Years Hypokali Mie Ver Changes Elektrolytst, Hyponatri chemistry and bilirubin. He could not find Lich Elektrolytst Requirements exclude Lich administered by the association in this study, because cisplatin-induced U again pretreated patients. Electrolyte imbalance can Tubulussch induced earlier. Can, t patients developed toxicity Grade Nonhaematological. Two patients had DLT fatigue quality t And grade are H Rverlust. Due to the toxicity of t of t Nonhaematological patients. A dose reduction of tipifarnib and four patients audiometric in the gemcitabine and cisplatin analysis Three patients had a normal value for audiometry at first, but the assessment test abnormal far. The first patient was treated with cisplatin and had a class mgm